Glioma Clinical Trials

49 studies are recruiting for glioma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

   The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following ques…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama

   Locations

   30 in total

   Run by

   Black Diamond Therapeutics, Inc.

   See if you can join NCT07326566 on ClinicalTrials.gov

2. Development of MRF for Characterization of Brain Tumors After Radiotherapy

   The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced qua…

   Stage

   Not phased

   Ages

   18 to 60

   Site

   University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio

   Locations

   2 in total

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT06101069 on ClinicalTrials.gov

3. MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas

   This trial uses magnetic resonance elastography (MRE) to estimate tissue stiffness (hardness or softness of the tissue) in tissue that is affected by radiation treatment (radiation necrosis) and tumor tissue that has come back (recurrent) after treatment in patients with gliomas. Diagnostic procedu…

   Stage

   Not phased

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT04373720 on ClinicalTrials.gov

4. Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

   The goal of this clinical research study is to learn about the safety and effects of M032 given directly into the tumor in children and adults with DMG and who have received standard-of-care radiation therapy.

   Stage

   Phase 1

   Ages

   3 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07076498 on ClinicalTrials.gov

5. A Study of Mirdametinib in People With Central Nervous System Tumors

   The purpose of this study to find out whether mirdametinib is a safe and effective treatment for Central Nervous System/CNS tumors (glioma and neurohistiocytosis).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07539441 on ClinicalTrials.gov

6. Assessing Brain Metabolism Using MRS With Deuterated Glucose

   This study will investigate the use of Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) with deuterated glucose (2H-glucose) to detect dynamic glucose uptake in the brain.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT06594315 on ClinicalTrials.gov

7. Glioma Developmental and HyperActive Ras Tumor (DHART) Board

   This study will collect medical records, scan results, and complete surveys to create a registry about people with a neurofibromatosis type 1-associated brain tumor (NF1-associated glioma). A registry is a collection of health information about individuals, and it is usually focused on a specific d…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05489783 on ClinicalTrials.gov

8. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

   This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Alabama, Birmingham, Alabama

   Locations

   61 in total

   Run by

   Nuvation Bio Inc.

   See if you can join NCT05303519 on ClinicalTrials.gov

9. Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

   This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson. This may help doctors use testing information on tumors to identify clinical trials that may be…

   Stage

   Not phased

   Ages

   Any age

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT01772771 on ClinicalTrials.gov

10. Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions

    This clinical trial evaluates the use of microdialysis catheters during surgery to collect biomarkers, and studies the feasibility of intra- and post-operative microdialysis during neurosurgery for central nervous system malignancies. A biomarker is a measurable indicator of the severity or presenc…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT04047264 on ClinicalTrials.gov

11. Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

    Background: Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor; survival ranges from 5.2 months to 39 months. Most tumors come back within months or years after treatment, and when they do, they are worse: Overall survival drops to less than 10 months. …

    Stage

    Phase 1

    Ages

    18 to 120

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT06344130 on ClinicalTrials.gov

12. PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

    Background: About 90,000 new cases of brain and spinal cord tumors are diagnosed annually in the United States. Most of these tumors are benign; however, about 30% are malignant, and 35% of people with malignant tumors in the brain and spinal cord will die within 5 years. Many of these people have …

    Stage

    Phase 1

    Ages

    18 to 120

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT06161519 on ClinicalTrials.gov

13. A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

    This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful. The purpose of this study is to find out the highest dose of BI 764532 that pe…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California Irvine, Orange, California

    Locations

    12 in total

    Run by

    Boehringer Ingelheim

    See if you can join NCT05916313 on ClinicalTrials.gov

14. Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

    A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.

    Stage

    Phase 4

    Ages

    18 and older

    Site

    UCI Irvine Health, Orange, California

    Locations

    2 in total

    Run by

    Rigel Pharmaceuticals

    See if you can join NCT07486713 on ClinicalTrials.gov

15. A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial

    This clinical trial tests how well a digital treatment platform using a mobile application works for the delivery of home-based sequential therapy in patients with glioma. Access to specialized neuro-oncology care in the United States for patients with glioma is critically deficient. Care at center…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Locations

    2 in total

    Run by

    Mayo Clinic

    See if you can join NCT07074756 on ClinicalTrials.gov

16. Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

    This is a pilot clinical trial determining the effect of a Methionine-reduced diet on serum levels in subjects with solid tumors. These are subjects who will receive systemic standard of care cancer therapy.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT07628634 on ClinicalTrials.gov

17. Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

    Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill glioblastoma tumor cells. Objective: To test LMP744 in peop…

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Institute of Neurological Disorders and Stroke (NINDS)

    See if you can join NCT07416188 on ClinicalTrials.gov

18. A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

    This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic profiles and preliminary clinical activity in participants with a high gra…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    3 in total

    Run by

    Tetragon Biosciences Ltd

    See if you can join NCT07464925 on ClinicalTrials.gov

19. Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

    This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Hartford Healthcare Alliance (Data Collection Only), Hartford, Connecticut

    Locations

    10 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05188508 on ClinicalTrials.gov

20. Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease

    This early phase I trial tests the safety, side effects and how well medication combinations of dasatinib, quercetin, fisetin, temozolomide, LMP744, and autologous tumor lysate particle only (TLPO) vaccine work in treating patients with glioma for which the patient has received treatment in the pas…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT07025226 on ClinicalTrials.gov

21. Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

    High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patient population. This clinical trial investigates a novel imagi…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Eben Rosenthal

    See if you can join NCT07210632 on ClinicalTrials.gov

22. Hyperpolarized Imaging in Diagnosing Participants With Glioma

    This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.

    Stage

    Phase 1

    Ages

    19 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Susan Chang

    See if you can join NCT03739411 on ClinicalTrials.gov

23. Sitagliptin in Recurrent/Progressive Grade 4 Glioma

    Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Iowa Health Care, Iowa City, Iowa

    Run by

    Kailin Yang, MD, PhD

    See if you can join NCT07541781 on ClinicalTrials.gov

24. Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients

    In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired throug…

    Stage

    Not phased

    Ages

    18 to 99

    Site

    Moores Cancer Center, San Diego, California

    Run by

    Jona Hattangadi-Gluth

    See if you can join NCT05576103 on ClinicalTrials.gov

25. Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

    The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma. The main questions the study aims to answer are: * Progression-free and overall survival of patients receiving this combination; * Quality of Li…

    Stage

    Phase 1

    Ages

    19 and older

    Site

    Mayo Clinic, Rochester, Minnesota

    Locations

    2 in total

    Run by

    Aveta Biomics, Inc.

    See if you can join NCT06011109 on ClinicalTrials.gov